Synopsis Globally, one in five men aged >50 years is predicted to experience an osteoporotic fracture due to the treatment gap in osteoporosis and the scarcity of bone-forming agents. Thus, a need exists for new strategies. This study aimed to assess the safety and efficacy of romosozumab in men with osteoporosis. This week’s “ MED FACT ” discusses a clinical trial from The Journal of Clinical Endocrinology & Metabolism, “ A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men with Osteoporosis ”.
Authors: Lewiecki EM, Blicharski T, Goemaere S et al. Key Takeaways: Romosozumab is a well-tolerated and promising bone-forming treatment for men with osteoporosis. Objective: To assess the safety and efficacy of romosozumab in men with osteoporosis Study Type: Phase III, multicenter, double-blind, Randomized Placebo-Controlled Trial Participants:…
